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Methods: An open label, randomised controlled pilot study comparing blood concentrations of reactive oxygen species (ROS), interleukin 6 (IL-6) and neuron-specific enolase (NSE) between two different fractions of inspired oxygen in severe TBI patients on mechanical ventilation. [12.2-26.3] , P = 0.62). There were no differences between groups in the incidence of pulmonary complications. Conclusion: Higher fraction of inspired oxygen did not increase blood concentrations of markers of oxidative stress, inflammation or neurological injury or the incidence of pulmonary complications in severe TBI patients on mechanical ventilation. Traumatic brain injury (TBI) is the leading cause of death in young people, 1 and disability is a severe problem among survivors. [2] [3] [4] In TBI patients, regional brain ischaemia is a common finding, which may be related to low tissue oxygen tension (PtiO 2 ). 5, 6 The use of high fractions of inspired oxygen is one intervention used to correct low PtiO 2 . Moderate hyperoxia increases the cerebral aerobic metabolism 7 and has been suggested as a means of improving outcomes after TBI. [7] [8] [9] Experimental studies indicate that normobaric hyperoxia improves the perilesional tissue metabolic rate of oxygen. 10, 11 On the other hand, normobaric hyperoxia is associated with increased cerebral excitotoxity 12 and increased PaO 2 has direct vasoconstrictive effect on arterioles that in turn reduces cerebral blood flow. 13 One mechanism by which oxygen toxicity occurs is the production and accumulation of excessive reactive oxygen species (ROS), [14] [15] [16] which can potentially exacerbate brain injury. 17 Furthermore, TBI is associated with the activation of several inflammatory pathways, which may be modulated by the amount of oxygen available in tissue. The effects of hyperoxia on inflammation are not well understood: normobaric hyperoxia increases inflammatory marker release, 18 whereas hyperbaric hyperoxia has been shown to reduce levels of the proinflammatory marker interleukin 6 (IL-6) 19 , which is associated with the neurological outcome. 18 However, using a high fraction of inspired oxygen has also been associated with pulmonary adverse events, such as ventilation-perfusion mismatch, pulmonary oedema and inflammation. 20 A high concentration of inspired oxygen may cause the formation of lung atelectasis, and some studies even suggest an increase in mortality in general intensive care unit (ICU) patients. 19, 21 There are no clinical studies on the effect of the prolonged use of normobaric hyperoxia on inflammatory markers, markers of oxidative stress and neurological injury in TBI. Accordingly, in this pilot study, we compared the effect of a ventilation strategy aiming at moderate hyperoxaemia (FiO 2 0.70) to a standard oxygen fraction (FiO 2 0.40) in patients with severe traumatic brain injury (Glasgow Coma Score (GCS)< 8). We hypothesised that a strategy using a higher oxygen fraction would result in an alleviated inflammatory response and lower markers of neurological injury, without significantly increasing oxidative stress.
Materials and methods
Trial design, participants and setting Exclusion criteria were as follows: age < 18 or > 65 years, anticipated brain death in 12 h or otherwise moribund patient expected to die in 24 h, expected need for mechanical ventilation < 24 h, insufficient oxygenation assessed by a clinician or multiple trauma patients with brain injury and severe abdominal, thoracic or pelvic injury possibly affecting oxygenation, no consent, insufficient oxygenation with the treatment modality of the lower oxygenation group (Pa02 < 13 kPa or SpO 2 < 95% with Fi02 0.40 and PEEP of 10) or oxygenation failure probable during ICU care, penetrating TBI, suspected pregnancy (perform urinary or serological pregnancy test if suspected).
Randomisation procedure
We used sealed, opaque envelopes to randomly divide patients into two intervention groups. Patients were stratified according to TBI severity (group GCS 3-5 and group GCS 6-8), whether they had a surgically removed haematoma prior to ICU admission or diffuse brain injury, or whether they had decompressive craniectomy performed prior to randomisation. Patients had to be included within 36 h from injury and 18 h from admission to ICU. To exclude those patients with a GCS< 8 due to a concomitant intoxication and those who regained consciousness immediately following operative treatment, a sedation break was performed in the ICU and this measured GCS was used as the inclusion criterion.
Study intervention
Patients were randomly assigned to receive either FiO 2 0.40 or 0.70 of inspired oxygen during the period of mechanical ventilation for a maximum time of 14 days. Fi 0.40 and Fi 0.70 groups were chosen by a consensus decision in the study management committee. Positive end expiratory pressure (PEEP) of 8-10 was used to minimise lung atelectasis. Otherwise, the patient treatment was at the discretion of the treating clinician, but it was recommended that the Brain Trauma Foundation Guidelines be followed (Appendix S1).
Laboratory sample handling and analysis Laboratory samples were centrifuged and frozen at À70°C. Serum was used for NSE analyses and plasma for IL-6, ROS and RNS analyses.
Neuron-specific enolase was analysed with electrochemiluminescence immunoassay (ECLIA). The reagent used in analysis was neuron-specific enolase (NSE) (catalogue number 12133113 122, Roche Diagnostics GmbH, Mannheim, Germany) and the instrumentation used was the Cobas e 601 analyser (Hitachi High Technology Co., Tokyo, Japan). The NSE was analysed only once. This methodology is in clinical practise and our accredited Kuopio University Hospital laboratory analysed all samples. The concentration of IL-6 in the plasma was measured using a Sandwich enzymelinked immunosorbent assay (ELISA) kit (BioLegend, San Diego, CA, USA) and the data were calculated with computer-based, curvefitting software, after which the concentrations of the samples were multiplied by the appropriate dilution factor (1 : 1). IL-6 was measured in duplicate.
Reactive oxygen species and RNS plasma levels were measured using the OxiSelect TM In Vitro ROS/RNS Assay Kit (Cell Biolabs, Inc., San Diego, CA, USA). All the patients were sedated with propofol. Glycerol is an ingredient in propofol solution. In this analysis, the concentration of glycerol in propofol was 2.5% and in the compactible concentration range below 10%. The ROS assay was performed as per the manufacturer's instructions. ROS and RNS were measured in duplicates.
Outcome variables and statistical considerations Originally, when this study was designed, the primary intention was to evaluate neurological outcome at 6 months. Power analysis based on a risk of poorer outcome than expected (death or severe neurological injury) with 80% power at 5% significance level resulted at sample size of 500 patients (250 patients in both oxygen groups) to detect a 10% decrease in poor outcome. However, owing to a lack of funding and a slow recruitment rate, the study is presented as a pilot study with laboratory markers as the surrogate outcome during the three-first days. The analysis plan was approved in advance by all authors. The agreed primary outcomes for this were the levels of ROS, IL-6 and NSE over time during ICU care. It was decided to focus on patients remaining in the ICU for longer than 40 h. Post hoc power analysis (power 80% and P = 0.05) based on mean values and standard deviation of ROS/RNS values on Day 1 gave a sample size of 123 patients.
Data collection
Data were collected with paper case record forms (CRF), which included patient demographics, comorbidities, medications, pre-hospital treatment with relevant time points, clinical status at arrival and type of trauma. Daily data collection in the ICU included vital signs, neurological status and acute physiology and chronic health evaluation (APACHE II). 22 Also recorded were sequential organ failure assessment (SOFA), 23 chest X-rays, head computer tomography (CT) classification according to the Marshall classification, 24 fluid balance, blood transfusion and interventions aiming at decreasing intracranial pressure, daily blood samples (arterial blood gases at least three times a day) and respiratory management (ventilatory settings, PaO 2 : FiO 2 ratio and static compliance). Study-specific laboratory markers ROS/RNs, IL-6 and NSE were measured at admission, Day 1 and/or Days 2 and 3. The Extended Glasgow Outcome Scale (GOSE) 25 was assessed by a blinded neurologist at 6 months, after contacting the patient or patient's representative by phone.
Statistical analysis
Categorical data are presented as absolute numbers, with percentages in parentheses. For comparing categorical data, we used a two-sided chi-squared test or Fisher's exact test when appropriate. We tested all continuous data for skewness, and these data are presented as medians with interquartile ranges (IQR), unless stated otherwise. We used the non-parametric Mann-Whitney U-test for univariate comparison. Group levels of ROS, IL-6 and NSE over time were compared by a linear mixed model, using a variance component structure. The change of ROS, IL-6 and NSE levels in the groups over time was compared using the nonparametric Friedman test (three time points) or Wilcoxons signed-rank test (two time points). We used statistical software SPSS version 22 (IBM SPSS Statistics, Armonk, NY, USA).
Ethical considerations
This pilot study was conducted according to the principles of the Helsinki Declaration. The ethics committee of Northern Savo, Finland approved the study protocol number 93/2009. Informed consent was obtained by the patient representative prior to the study intervention. If the patient regained capacity to give informed consent, a deferred patient consent was obtained.
Results
Of a total of 380 screened patients, 65 patients were included, with 27 (42%) randomised to the FiO 2 0.40 group and 38 (58%) to the FiO 2 0.70 group (Fig. 1) . Altogether, 23 study patients had incomplete laboratory tests at Day 2 or 3 and were subsequently excluded from the analysis of laboratory markers, but their clinical outcomes are presented. Patient baseline characteristics are presented in Table 1 . The mean patient age was 43 + 17 years in the FiO 2 0.4 group and 45 + 13 in the FiO 2 0.70 group (P = 0.97). Admission SOFA and APACHE II scores were equal in both groups and no statistical differences in the admission GCS were observed ( Table 1 ). The haemoglobin concentration was lower in the FiO 2 0.70 group (125 + 2 g/l) than in the FiO 2 0.40 group (131 + 2 g/l, P = 0.02). The risk of poor outcome and death calculated with The International mission for prognosis and analysis of clinical trials in TBI prognostic calculator (TBI-IMPACT) 26 was higher in the FiO 2 0.70 group that FiO 2 0.40 group, respectively (0.56 + 0.20 vs. 0.45 + 0.15, P < 0.03 and 0.35 + 0.16 vs. 0.25 + 0.15, P < 0.02). In the FiO 2 0.70 group, there were more patients with poor GCS and a mass lesion in CT-scan Table 1 ).
Study intervention
In the FiO 2 0.40 group, the mean FiO 2 was 0.42 and in the FiO 2 0.70 group it was 0.68 (P < 0.001). The median length of the study intervention was 213 (116-318) h in the Patients in the higher oxygen group had significantly higher mean arterial blood oxygen tension than patients in the lower oxygen group (P < 0.001). A higher oxygen fraction resulted, as expected, in significantly higher mean oxygen tension, without differences in mean carbon dioxide ( Table 2, Fig. 2 ). The oxygen tension in arterial blood was 16.59 kPa in the FiO 2 0.40 group and 29.09 kPa in the FiO 2 0.70 group (P < 0.001).
Differences in laboratory markers
Blood levels of ROS, IL-6 and NSE are shown in Fig. 3 
Pulmonary complications and clinical outcomes
The incidence of acute respiratory distress syndrome (ARDS), atelectasis formation and pneumonia were similar in both groups (ARDS P = 0.067, atelectasis formation P = 0.722 and pneumonia P = 0.534). The P /F-ratio was similar in both groups, P = 0.113 (Table 2 , Figure S1 ).
Discussion

Key findings
In this pilot study conducted in mechanically ventilated patients with severe TBI, the use of an inspired oxygen fraction of 0.70 compared to 0.40 did not increase markers of oxidative stress, inflammation or neurological injury, measured by levels of ROS, IL-6 and NSE. Although the study is underpowered, the results suggest that the use of a higher oxygen fraction is safe and does not result in more pulmonary complications or a prolonged need for mechanical ventilation. Future studies are warranted to clarify the role of normobaric hyperoxia in TBI patients.
Comparison to previous studies
Exposure to hyperoxia has been investigated in both animal and human studies. In animal studies, the effects of hyperoxia are contradictory. In animal brain injury and ischaemia resuscitation models, Ahn and by Hazeltom showed that hyperoxia results in an increased inflammatory response and that normoxaemia reduces oxidative damage to the brain, measured by levels of ROS. 17, 27 In these studies, the animals were exposed to hyperoxia for 1 h only. The vast majority of animal studies suggest that short periods of hyperoxia do not promote additional free radical production, 28 and the effects of hyperoxia on oxidative stress seem to be timedependent. In the present pilot study, although the exposure to hyperoxia lasted for 165 + 108 h, we failed to show any difference in the oxidative stress between groups. Fujita et al 9 studied the effect of early-stage hyperoxaemia on neurological outcome in patients with TBI. They found hyperoxia to be beneficial in terms of neurological outcome and survival although the intervention lasted for only 24 h and these patients were either fever controlled or experiencing mild hypothermia.
Most studies on hyperoxia in patients with TBI are retrospective and assess the impact of hyperoxia on the crude outcome. Generally, hyperoxia is associated with increased mortality, but the interpretation of such results is challenging, owing to the heterogeneity of the studies. 29 In humans, Puccio et al 30 studied the effect of hyperoxia on patients with severe TBI. They ventilated the patients for 2 h with FiO 2 1.0 and found that hyperoxia did not increase oxidative stress markers. This is in accordance with our pilot study, which suggests that even prolonged exposure to higher oxygen does not increase oxidative stress, inflammation or neurological injury.
The association of oxidative stress and inflammation is complex. In in vitro models, hyperoxia has been shown to increase ROS, which in turn results in the generation of intracellular inflammatory markers such as IL-6 and IL-8 in lung tissue. 15 Theoretically, hyperoxia-induced lung injury results from direct oxygen toxicity and the accumulation of inflammatory mediators in the lung tissue. 15 Hyperoxia-induced lung injury (HALI) is proportional to PaO 2 and exposure duration. 31 However, the duration of Continuous data are presented as mean (SD) or median (IQR). For normally distributed data, the v 2 -test (Bonferroni correction) was used and, when the expected value was below 5, the Fischer's exact test was used. For non-parametric continuous data, the Mann-Whitney U-test was used. SD, standard deviation; IQR, interquartile range; P/R ratio, ratio of arterial oxygen partial pressure to fractional inspired oxygen; ICU, intensive care unit; ARDS, Acute respiratory distress syndrome; eGOSE, Extended Glasgow outcome scale. hyperoxia leading to pulmonary toxicity is unknown. 32 Conservative oxygen therapy is associated with less radiological atelectasis formation, but its clinical impact is unclear. 33 In a retrospective observational study, hyperoxia was independently associated with ventilatorinduced pneumonia, 34 but another study found that hyperoxia did not affect ICU or hospital length of stay. 35 The present pilot study did not exhibit any adverse effects of hyperoxia on lungs; indeed, to the contrary, the FiO 2 0.40 group had a longer ICU length of stay.
It must be kept in mind that neuroinflammation has both beneficial and detrimental effects on the brain after TBI. It promotes the reparation and regeneration processes of the primary injury; on the other hand, it may worsen secondary brain injury. 36 In our pilot study, even NSE concentrations were equal in both study groups, suggesting that hyperoxia in this complex setting does not negatively affect brain tissue.
We are not aware of any other randomised studies with severe TBI in which hyperoxia has been studied to a standard of FiO 2 of 0.40. Generally, conservative oxygen therapy is associated with a shorter duration of mechanical ventilation 33, 37 and more ventilator-free days, without an impact on ICU mortality. 37 The present pilot study was unable to confirm these findings.
Limitations
First, the present pilot study was designed to be a randomised controlled trial with a patientcentred outcome as the endpoint. However, owing to lack of funding and slow recruitment, the study was terminated and is therefore study is presented as a pilot study with laboratory markers as primary outcome. Secondly, there was a difference in severity of TBI according to the TBI-IMPACT model between groups, and this may have influenced the study findings.
Conclusion
In the current pilot study, prolonged use of an inspired fraction of oxygen of 0.70 compared to 0.40 did not affect the blood levels of markers of oxidative stress, inflammation or neurological injury. In addition, we found no difference in pulmonary complications between the groups. Further studies are needed to evaluate the impact of using higher oxygen fractions on neurological outcome after severe TBI.
